Using the Conture® Multi-Lumen Balloon to Deliver Accelerated Partial Breast Brachytherapy

A Multi-site Prospective, Non Randomized Study Utilizing the Conture® Multi-Lumen Balloon (MLB) Breast Brachytherapy Applicator to Deliver Accelerated Partial Breast Irradiation: Analysis of Dosimetric Success, Local Tumor Control, Cosmetic Outcome, Acute and Chronic Toxicity, and Clinical Scenarios for Optimal Use

Status

Terminated

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00699101

Enrollment

342

Registered

2008-06-17

Start date

2008-06-30

Completion date

2013-06-30

Last updated

2013-06-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Keywords

Breast Cancer, Conture®, Brachytherapy

Brief summary

This multiple site, prospective, non-randomized study has been designed to compile information on the efficacy of the Contura™ MLB in delivering APBI in appropriately selected patients through evaluation of dosimetric success as compared with a single central lumen balloon device and through treatment outcomes.

Detailed description

Data collected during this study will include baseline patient demographics, information related to the time of implant, radiation therapy details, and removal of the device as well as recurrence data, cosmetic outcomes and toxicities. The patient's follow-up data will be collected during the patient's standard follow-up visits.

Interventions

DEVICEConture Multi-Lumen Balloon

Placement of the balloon in a separate procedure using ultrasound guidance after surgery for breast cancer.

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

50 Years to No maximum

Healthy volunteers

Inclusion criteria

* Able and willing to sign informed consent * Age 50 or older at diagnosis * Life expectancy greater than 10 years (excluding diagnosis of breast cancer). * Surgical treatment of the breast must have been lumpectomy. The margins of the resected specimen must be histologically free of tumor (negative surgical margins per NSABP criteria). * On histologic examination, the tumor must be DCIS or invasive breast carcinoma. For patients with invasive breast cancer, an axillary staging procedure must be performed. Either: 1. sentinel node biopsy (SNB) alone if sentinel node(s) is/are negative; or 2. axillary dissection (minimum of six axillary nodes removed); and 3. the axillary node(s) must be pathologically negative. * The T stage must be Tis, T1, or T2. If T2, the tumor must be ≤ 3.0 cm in maximum diameter. * Estrogen receptor positive tumor

Exclusion criteria

* Age \< 50 at diagnosis (regardless of histology) * Pregnant or breast-feeding (if appropriate, patient must use birth control during the study) * Active collagen-vascular disease * Paget's disease of the breast * History of DCIS or invasive breast cancer * Prior breast or thoracic RT for any condition * Multicentric carcinoma (DCIS or invasive) * Synchronous bilateral invasive or non-invasive breast cancer * Surgical margins that cannot be microscopically assessed or that are positive or close * Positive axillary node(s) * T stage of T2 with the tumor \> 3 cm in maximum diameter or a T stage \> 3 * Estrogen receptor negative tumor

Design outcomes

Primary

Measure	Time frame
Dosimetric efficacy of the Contura™ MLB with the historical efficacy rate of a single central lumen balloon device.	5 years

Secondary

Measure	Time frame
Quantify the dosimetric improvement of multi-lumen use over single lumen use through dosimetric comparison.	5 years

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026